AACR 2024 – Transgene gets a “vaccine” boost
Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.
AACR 2024 – Medicenna looks for a cytokine renaissance
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.
AACR 2024 – a first look at Astra’s ATM inhibitor
One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.
AACR 2024 – Vincerx overreaches
The company's comparison of its ADCs to Enhertu seems farfetched.
AACR 2024 – Astra plays up PARP1 inhibition
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.
AACR 2024 – BioNTech sees pancreatic promise amid neoantigen delays
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
AACR 2024 – Akeso impresses in stomach cancer
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
AACR 2024 preview – Lag3, TIGIT and more
BeiGene has a strong presence at this year’s AACR, which features several notable duels.